241 related articles for article (PubMed ID: 28833329)
1. Population pharmacokinetics and Bayesian estimation of tacrolimus exposure in Chinese liver transplant patients.
Chen B; Shi HQ; Liu XX; Zhang WX; Lu JQ; Xu BM; Chen H
J Clin Pharm Ther; 2017 Dec; 42(6):679-688. PubMed ID: 28833329
[TBL] [Abstract][Full Text] [Related]
2. Impact of Donor and Recipient
Shao J; Wang C; Fu P; Chen F; Zhang Y; Wei J
Ann Pharmacother; 2020 Jul; 54(7):652-661. PubMed ID: 31888346
[No Abstract] [Full Text] [Related]
3. Effects of CYP3A5 genotypes, ABCB1 C3435T and G2677T/A polymorphism on pharmacokinetics of Tacrolimus in Chinese adult liver transplant patients.
Zhu L; Yang J; Zhang Y; Jing Y; Zhang Y; Li G
Xenobiotica; 2015; 45(9):840-6. PubMed ID: 25869250
[TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetic analysis and dosing guidelines for tacrolimus co-administration with Wuzhi capsule in Chinese renal transplant recipients.
Jing Y; Kong Y; Hou X; Liu H; Fu Q; Jiao Z; Peng H; Wei X
J Clin Pharm Ther; 2021 Aug; 46(4):1117-1128. PubMed ID: 33768546
[TBL] [Abstract][Full Text] [Related]
5. Association of ABCB1, CYP3A4*18B and CYP3A5*3 genotypes with the pharmacokinetics of tacrolimus in healthy Chinese subjects: a population pharmacokinetic analysis.
Shi XJ; Geng F; Jiao Z; Cui XY; Qiu XY; Zhong MK
J Clin Pharm Ther; 2011 Oct; 36(5):614-24. PubMed ID: 21916909
[TBL] [Abstract][Full Text] [Related]
6. The pharmacokinetics of tacrolimus in peripheral blood mononuclear cells and limited sampling strategy for estimation of exposure in renal transplant recipients.
Wang XH; Shao K; An HM; Zhai XH; Zhou PJ; Chen B
Eur J Clin Pharmacol; 2022 Aug; 78(8):1261-1272. PubMed ID: 35536394
[TBL] [Abstract][Full Text] [Related]
7. Comparative clinical trial of the variability factors of the exposure indices used for the drug monitoring of two tacrolimus formulations in kidney transplant recipients.
Marquet P; Albano L; Woillard JB; Rostaing L; Kamar N; Sakarovitch C; Gatault P; Buchler M; Charpentier B; Thervet E; Cassuto E
Pharmacol Res; 2018 Mar; 129():84-94. PubMed ID: 29229354
[TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetic modelling and design of a Bayesian estimator for therapeutic drug monitoring of tacrolimus in lung transplantation.
Monchaud C; de Winter BC; Knoop C; Estenne M; Reynaud-Gaubert M; Pison C; Stern M; Kessler R; Guillemain R; Marquet P; Rousseau A
Clin Pharmacokinet; 2012 Mar; 51(3):175-86. PubMed ID: 22339449
[TBL] [Abstract][Full Text] [Related]
9. Population pharmacokinetics of tacrolimus and CYP3A5, MDR1 and IL-10 polymorphisms in adult liver transplant patients.
Li D; Lu W; Zhu JY; Gao J; Lou YQ; Zhang GL
J Clin Pharm Ther; 2007 Oct; 32(5):505-15. PubMed ID: 17875118
[TBL] [Abstract][Full Text] [Related]
10. Tacrolimus population pharmacokinetics according to CYP3A5 genotype and clinical factors in Chinese adult kidney transplant recipients.
Zhang HJ; Li DY; Zhu HJ; Fang Y; Liu TS
J Clin Pharm Ther; 2017 Aug; 42(4):425-432. PubMed ID: 28401703
[TBL] [Abstract][Full Text] [Related]
11. Effects of Postoperative Day and NR1I2 on Tacrolimus Clearance in Chinese Liver Transplant Recipients-A Population Model Approach.
Lu Y; Xu L; Cui J; Shen S; Li X
Clin Pharmacol Drug Dev; 2021 Nov; 10(11):1385-1394. PubMed ID: 34133842
[TBL] [Abstract][Full Text] [Related]
12. Population pharmacokinetics and Bayesian estimation of tacrolimus exposure in renal transplant recipients on a new once-daily formulation.
Benkali K; Rostaing L; Premaud A; Woillard JB; Saint-Marcoux F; Urien S; Kamar N; Marquet P; Rousseau A
Clin Pharmacokinet; 2010 Oct; 49(10):683-92. PubMed ID: 20818834
[TBL] [Abstract][Full Text] [Related]
13. Effect of CYP3A5 and ABCB1 Gene Polymorphisms on Tacrolimus Blood Concentration in Renal Transplant Recipients.
Yildirim E; Şahin G; Kaltuş Z; Çolak E
Clin Lab; 2019 Nov; 65(11):. PubMed ID: 31710427
[TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetic study of tacrolimus in pediatric patients with primary nephrotic syndrome: A comparison of linear and nonlinear Michaelis-Menten pharmacokinetic model.
Huang L; Liu Y; Jiao Z; Wang J; Fang L; Mao J
Eur J Pharm Sci; 2020 Feb; 143():105199. PubMed ID: 31862313
[TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetic analysis of tacrolimus early after Chinese pediatric liver transplantation.
Yang JW; Liao SS; Zhu LQ; Zhao Y; Zhang Y; Sun XY; Rao W; Qu W; Li WZ; Sun LY
Int J Clin Pharmacol Ther; 2015 Jan; 53(1):75-83. PubMed ID: 25207550
[TBL] [Abstract][Full Text] [Related]
16. The interactions of age, genetics, and disease severity on tacrolimus dosing requirements after pediatric kidney and liver transplantation.
de Wildt SN; van Schaik RH; Soldin OP; Soldin SJ; Brojeni PY; van der Heiden IP; Parshuram C; Nulman I; Koren G
Eur J Clin Pharmacol; 2011 Dec; 67(12):1231-41. PubMed ID: 21698374
[TBL] [Abstract][Full Text] [Related]
17. Limited Sampling Strategy for the Estimation of Tacrolimus Area Under the Concentration-Time Curve in Chinese Adult Liver Transplant Patients.
Liu XX; Xu BM; Chen H; Song YY; Yang WH; Chen B
Pharmacology; 2016; 98(5-6):229-241. PubMed ID: 27449772
[TBL] [Abstract][Full Text] [Related]
18. Effects of CYP3A5, ABCB1 and POR*28 polymorphisms on pharmacokinetics of tacrolimus in the early period after renal transplantation.
Ling J; Dong LL; Yang XP; Qian Q; Jiang Y; Zou SL; Hu N
Xenobiotica; 2020 Dec; 50(12):1501-1509. PubMed ID: 32453653
[TBL] [Abstract][Full Text] [Related]
19. Dose tailoring of tacrolimus based on a non-linear pharmacokinetic model in children with refractory nephrotic syndrome.
Li L; Zhu M; Li DY; Guo HL; Hu YH; Xu ZY; Jing X; Chen F; Zhao F; Li YM; Xu J; Jiao Z
Int Immunopharmacol; 2021 Sep; 98():107827. PubMed ID: 34284341
[TBL] [Abstract][Full Text] [Related]
20. Population pharmacokinetics and pharmacogenetics of tacrolimus in healthy Chinese volunteers.
Xue L; Zhang H; Ma S; Rui JZ; Miao LY
Pharmacology; 2011; 88(5-6):288-94. PubMed ID: 22075549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
